• In late April 2026, CONMED Corporation reported first-quarter results with sales of US$317.05 million and higher earnings, raised its full-year 2026 revenue outlook to US$1.35–US$1.38 billion, and confirmed it had completed the divestiture of its remaining gastroenterology portfolio.
• Management’s decision to exit lower-margin gastroenterology products while simultaneously upgrading guidance and signaling interest in disciplined acquisitions highlights a sharpening focus on higher-margin surgical platforms and capital deployment.
• We’ll now examine how CONMED’s higher 2026 revenue guidance, despite the gastroenterology divestiture, reshapes the company’s broader investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

CONMED Investment Narrative Recap

To own CONMED, you need to believe its focus on minimally invasive surgery platforms like AirSeal, Buffalo Filter and BioBrace can offset past execution issues and heavy dependence on hospital spending. The key near term catalyst remains evidence of margin improvement from portfolio simplification and operational fixes, while the biggest risk is that hospital capital budgets and elective procedure volumes stay soft. The latest quarter and guidance tweak support the margin story but do not remove that demand risk.

The most relevant update here is management’s slightly higher 2026 revenue guidance to US$1.35–US$1.38 billion, even after lowering expected gastroenterology sales due to the divestiture. This shows the company is leaning on higher value surgery platforms and currency tailwinds to keep the top line intact, which matters for investors watching whether portfolio pruning and operational improvements can translate into sustained earnings growth despite ongoing cost and competitive pressures.

Yet behind the upgraded outlook, investors should be aware that CONMED’s reliance on hospital capital spending still leaves it exposed if reimbursement pressures or budget cuts...

CONMED's narrative projects $1.6 billion revenue and $154.0 million earnings by 2028. This requires 5.7% yearly revenue growth and a $43.8 million earnings increase from $110.2 million today.

Uncover how CONMED's forecasts yield a $48.40 fair value, a 35% upside to its current price.

Exploring Other Perspectives

Some of the most pessimistic analysts were only assuming about US$1.5 billion of revenue and US$164.9 million of earnings by 2029, so compared with concerns about rising global cost controls and reimbursement cuts, their view paints a much tougher path than the consensus and the latest guidance, reminding you that reasonable people can disagree and that this new information could pull those expectations in very different directions.

Explore 4 other fair value estimates on CONMED - why the stock might be worth as much as 100% more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your CONMED research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free CONMED research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CONMED's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.